ReGelTec Announces First Patient Treated in U.S. IDE Clinical Trial for HYDRAFIL System to Treat Chronic Low Back Pain
The launch of the HYDRAFIL-D U.S. study follows the company's receipt of CE Mark for the HYDRAFIL System based on promising results of clinical studies performed outside the United States on 75 patients.
The launch of the HYDRAFIL-D U.S. study follows the company's receipt of CE Mark for the HYDRAFIL System based on promising results of clinical studies performed outside the United States on 75 patients. The studies showed that patients treated with HYDRAFIL experienced clinically and statistically significant improvements in pain and disability, with more than 80% improvement in Oswestry Disability Index (ODI) scores and greater than 70% reduction in Numeric Pain Rating Scale scores, with reductions sustained for two years in the 63 patients that have completed their two-year follow-up visit.
'An overwhelming majority of my chronic low back pain patients either do not want or are not good candidates for invasive spine surgeries, yet they continue to feel debilitated, without many treatment options,' said Dr. Amirdelfan. 'The early data on HYDRAFIL is compelling and promising for our subjects. I am excited to be working with ReGelTec and the other principal investigators to enroll the HYDRAFIL-D Study and evaluate the impact of HYDRAFIL on patients with degenerative disc disease.'
The HYDRAFIL-D study is a 225-patient, multicenter, single-blinded, randomized, controlled trial evaluating the safety and effectiveness of the HYDRAFIL System to support FDA approval. The study will measure improvements in pain and disability, reliance on opioid medications, and the need for invasive medical procedures in patients with chronic low back pain due to degenerative disc disease. The protocol includes an interim safety analysis when the first sixty patients complete their six-month follow-up visit. There are nine study sites currently enrolling patients in Birmingham, Ala.; Walnut Creek, Calif.; Greenwood Village, Colo.; Jasper, Ga.; Shreveport, La.; Edmond, Okla.; Tyler, Texas; Richmond, Virginia; and Calgary, Canada, with additional sites being added.
More than one in 10 U.S. adults suffer from chronic low back pain. 1 About 42% of this population, or more than 10 million Americans, has degenerative disc disease 2, a condition that is the largest contributor to chronic low back pain where intervertebral discs in the spine deteriorate and lose their height and volume. Degenerating discs cause vertebrae to move abnormally and inflame surrounding spinal structures, muscles, joints and nerves, resulting in pain in the back and sometimes the leg.
Performed in an outpatient procedure under local anesthesia, ReGelTec's HYDRAFIL System delivers a permanent hydrogel into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. When the hydrogel implant solidifies in the disc, it distributes the load and strain felt in that intervertebral segment to improve function and reduce the pain signaling to the brain.
'I have been working with doctors and scientists for more than twenty years to develop a treatment for chronic low back pain, and in HYDRAFIL, we believe we've built a low-risk, effective option to fill a major market need,' said Tony Lowman, the inventor of HYDRAFIL and founder of ReGelTec. 'We look forward to fully enrolling the trial and securing FDA approval for the HYDRAFIL System so that patients in the United States with degenerative disc disease can benefit from this innovative, minimally invasive treatment option.'
Patients interested in learning more about the HYDRAFIL-D Study can visit www.hydrafilstudy.com.
ABOUT REGELTEC, INC.
ReGelTec is a clinical-stage privately held biomedical company dedicated to developing and commercializing a percutaneous hydrogel implant for the treatment of chronic low back pain due to degenerative disc disease. ReGelTec's HYDRAFIL System is an outpatient disc augmentation procedure where a permanent hydrogel is delivered into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. For more information, please visit https://regeltec.com/.
1 Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-1694. doi: 10.1002/acr.22890. PMID: 26991822; PMCID: PMC5027174.
2 Michael J. DePalma, Jessica M. Ketchum, Thomas Saullo, What Is the Source of Chronic Low Back Pain and Does Age Play a Role?, Pain Medicine https://doi.org/10.1111/j.1526-4637.2010.01045.x
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
This Quantum Computing Stock Just Made an AI Breakthrough
Key Points The unique capabilities of quantum computers could accelerate the evolution of artificial intelligence (AI). In a bid to advance the AI field, D-Wave Quantum developed a new tool kit integrating AI with quantum devices. Sales of D-Wave's tech delivered $18.1 million, a 289% year-over-year increase through the first half of 2025. 10 stocks we like better than D-Wave Quantum › Artificial intelligence (AI) is a hot sector with forecasts predicting the market to grow from $244 billion in 2025 to over $800 billion by 2030. This astounding growth could be supercharged by the advent of quantum computers. Quantum machines possess the ability to complete intricate calculations that surpass the capacities of classic computers. Marrying quantum devices with AI opens up new possibilities not attainable today. That's what makes the release of AI tools by D-Wave Quantum (NYSE: QBTS) a significant development. The tool set enables integration with D-Wave's quantum computers. Does this melding of AI and quantum tech suggest D-Wave stock is worth investing in? To assess the opportunity, let's look into what the company is doing and whether now is the time to buy shares in D-Wave. Details of D-Wave's new AI features On Aug. 4, D-Wave rolled out new tools allowing AI software developers to experiment with its quantum computer processors. This tool kit integrates the company's quantum systems with PyTorch, a framework for building AI models that has become a leader in the space. D-Wave's tools provide a PyTorch neural network module, enabling the development and training of AI models using a quantum computer. Today, these models require massive computational power and energy. As a result, the cost to build AI is escalating. According to Dr. Alan Baratz, CEO of D-Wave, "Quantum computing's integration with AI and machine learning could offer scalable, energy-efficient solutions to address these issues and potentially offer enhanced AI capabilities." The company is already working with customers to advance the use of AI with quantum machines. For instance, it's partnering with the pharmaceutical division of Japan Tobacco to combine quantum systems and AI in the drug-discovery process. The impact of D-Wave's tech on financial performance Delivering the ability of quantum computers to assist with AI development is an impressive milestone. But how have D-Wave's technological advances helped the company? Through the first half of 2025, D-Wave's sales have skyrocketed 289% year over year to $18.1 million. Its Japan Tobacco partnership is an example of broader customer demand, as orders in the Asia-Pacific region have grown 83% over the past 12 months. Clients in the area seek to apply D-Wave's quantum tech to AI and other business challenges. As a result, the company is holding its first quantum computing conference in Tokyo on Sept. 17. Moreover, D-Wave's gross margin ticked up to 63.8% in the second quarter from 63.6% in the prior year. You want to see gross margin steadily rise, as it means the company is improving cost management and thereby growing gross profit, which improved 42% year over year for D-Wave to $2 million off $3.1 million in Q2 sales. However, D-Wave doesn't operate a profitable business. Its Q2 loss from operations reached $26.5 million, up from a loss of $18.8 million in 2024, as research and development costs grew more than 50% year over year to $12.7 million. The increase in D-Wave's expenses are to be expected, since developing cutting-edge technology is not easy -- or cheap. In fact, many tech companies operate at a loss for years as they pour earnings into building up their businesses. So D-Wave's situation is not uncommon. In addition, the company has amassed a sizable war chest of $819.3 million in cash and equivalents at the end of Q2. This brought Q2 total assets to $843.6 million versus total liabilities of $149.3 million. The solid balance sheet funds operations in the short term while the company ramps up sales and seeks strategic acquisitions. Evaluating whether to invest in D-Wave stock Do these factors mean now is the time to invest in D-Wave stock? One consideration is share-price valuation. This can be assessed using the price-to-sales (P/S) ratio, which measures how much investors are willing to pay for every dollar of revenue generated over the trailing 12 months. The chart shows D-Wave's P/S multiple has gone up since it plunged in April along with the broader stock market due to President Trump's aggressive tariff approach. As of Aug. 15, it's near previous peaks, suggesting D-Wave shares are pricey. The other consideration is that quantum computers suffer challenges that prevent them from becoming scalable and cost effective. These devices use atomic particles to perform computations, but the particles are sensitive to the slightest environmental disruption, such as vibrations or temperature fluctuations. D-Wave is working to overcome these challenges but so are its many competitors, and it could take years to solve the issues. As a result, investing in D-Wave is only for those with a high risk tolerance. A judicious approach is to wait for D-Wave's share price to drop before deciding to buy. Should you buy stock in D-Wave Quantum right now? Before you buy stock in D-Wave Quantum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and D-Wave Quantum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This Quantum Computing Stock Just Made an AI Breakthrough was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Walmart recalls shrimp possibly exposed to radioactive material
Walmart has recalled some shrimp products in 13 US states after one shipment of seafood tested positive for radioactive contamination. The US Food and Drug Administration said varieties of frozen shrimp sold under Walmart's Great Value label could have been exposed to a dangerous isotope in shipping containers. One sample of breaded shrimp tested positive for the substance, but this positive sample "did not enter US commerce", the FDA said. Consumers are advised to throw away recently bought Walmart shrimp that matches this description - and not to eat or serve it. "The health and safety of our customers is always a top priority," a Walmart spokesperson told the BBC. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate." The spokesperson added that consumers who bought the recalled products can visit any Walmart location for a full refund. The recalled shrimp was sold at Walmart locations in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, and shoppers in those states were advised to be cautious. It came from an Indonesian supplier that has since had multiple shipping containers denied entry to the US, the FDA said. One shipment tested positive for Cesium-137, the radioactive form of the chemical element Cesium. The amount contained in the tested shipment held by the FDA was not enough to pose acute harm to consumers, but exposure over time could pose an elevated risk of cancer by damaging living cells in the body, said FDA officials.
Los Angeles Times
2 hours ago
- Los Angeles Times
Don't eat these potentially radioactive shrimp, FDA warns
The U.S. Food and Drug Administration is warning people to avoid eating certain raw frozen shrimp sold in Walmart stores as the agency investigates possible contamination by Cesium-137, a radioactive isotope. U.S. Customs and Border Protection alerted the FDA to the detection of Cesium-137 in a single shipment of imported frozen shrimp from the Indonesia-based company PT. Bahari Makmur Sejati, which does business under the name BMS Foods. Officials have since detected the radioactive isotope at four ports across the nation: Los Angeles, Houston, Miami; and Savannah, Ga. The amount of Cesium-137 detected within the contaminated shipment would not pose an acute hazard to consumers. However, long-term consumption would pose an elevated risk of cancer. Bags of the frozen food product are sold under the brand name Great Value at Walmart stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. All containers and products that tested positive or alerted for Cesium-137 have been denied entry into the country, according to an FDA announcement on Tuesday. Federal officials are coordinating with Indonesian seafood regulatory authorities to investigate the root cause of the contamination. There have not been any reports of contaminated shrimp in the freezer section or within the U.S. food supply chain, authorities said. Cesium-137 can be found in soil, food and air, according to the Environmental Protection Agency. It is produced by nuclear fission for use in medical gauges and devices, but can also be a byproduct of nuclear reactors and weapons testing, the agency said. Though bags of frozen shrimp haven't tested positive for Cesium-137, officials say the product may have been prepared, packed or held in unsanitary conditions. Walmart has received shipments of the frozen food that were imported after the date of the first detection, but those specific shipments did not alert for contamination, officials said. Shoppers who purchased the following products should not consume eat or serve the frozen shrimp, but instead throw it away, authorities say: The FDA is currently recommending that Walmart completely recall the item. BMS Foods is also no longer allowed to import the products into the U.S. until the company addresses any potential issues.
